doi	section	n_itc	study_number	questions	answer	ttt_parsed	others	car_t_cells	atc_code	concept_class_id	concept_name	concept_code_ancestor_ATC 1st	concept_code_ancestor_ATC 2nd	concept_code_ancestor_ATC 3rd	concept_code_ancestor_ATC 4th	concept_name_ancestor_ATC 1st	concept_name_ancestor_ATC 2nd	concept_name_ancestor_ATC 3rd	concept_name_ancestor_ATC 4th
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	treatment_name_ipd	teprotumumab	teprotumumab	NA	FALSE	L04AA53	ATC 5th	teprotumumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1001/jamaophthalmol.2021.6284	methodology	1	NA	treatment_name_nonipd	intravenous methylprednisolone	intravenous methylprednisolone	NA	FALSE	H02AB04	ATC 5th	methylprednisolone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1002/edm2.259	methodology	1	NA	treatment_name_ipd	semaglutide 0.5  +  1 mg	semaglutide 0.5	NA	FALSE	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1002/edm2.259	methodology	1	NA	treatment_name_nonipd	dulaglutide 1.5 mg	dulaglutide 1.5 mg	NA	FALSE	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1007/bf03261873	methodology	1	NA	treatment_name_ipd	guanfacine extended-release low dose	guanfacine extended-release low dose	NA	FALSE	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists
10.1007/bf03261873	methodology	1	NA	treatment_name_nonipd	atomoxetine	atomoxetine	NA	FALSE	N06BA09	ATC 5th	atomoxetine; oral	N	N06	N06B	N06BA	NERVOUS SYSTEM	PSYCHOANALEPTICS	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	Centrally acting sympathomimetics
10.1007/bf03261873	methodology	2	NA	treatment_name_ipd	guanfacine extended-release mid dose	guanfacine extended-release mid dose	NA	FALSE	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists
10.1007/bf03261873	methodology	2	NA	treatment_name_nonipd	atomoxetine	atomoxetine	NA	FALSE	N06BA09	ATC 5th	atomoxetine; oral	N	N06	N06B	N06BA	NERVOUS SYSTEM	PSYCHOANALEPTICS	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	Centrally acting sympathomimetics
10.1007/bf03261873	methodology	3	NA	treatment_name_ipd	guanfacine extended-release high dose	guanfacine extended-release high dose	NA	FALSE	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists
10.1007/bf03261873	methodology	3	NA	treatment_name_nonipd	atomoxetine	atomoxetine	NA	FALSE	N06BA09	ATC 5th	atomoxetine; oral	N	N06	N06B	N06BA	NERVOUS SYSTEM	PSYCHOANALEPTICS	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	Centrally acting sympathomimetics
10.1007/s00432-021-03602-w	methodology	1	NA	treatment_name_ipd	regorafenib	regorafenib	NA	FALSE	L01EX05	ATC 5th	L01EX05	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1007/s00432-021-03602-w	methodology	1	NA	treatment_name_nonipd	cabozantinib	cabozantinib	NA	FALSE	L01EX07	ATC 5th	L01EX07	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1007/s11523-021-00803-8	methodology	1	NA	treatment_name_ipd	lenvatinib	lenvatinib	NA	FALSE	L01EX08	ATC 5th	L01EX08	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1007/s11523-021-00803-8	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab	atezolizumab	NA	FALSE	L01XC32	ATC 5th	atezolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s11523-021-00803-8	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab	bevacizumab	NA	FALSE	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-014-0167-z	methodology	1	NA	treatment_name_ipd	fingolimod	fingolimod	NA	FALSE	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s12325-014-0167-z	methodology	1	NA	treatment_name_nonipd	dimethyl fumarate	dimethyl fumarate	NA	FALSE	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1007/s12325-014-0167-z	methodology	2	NA	treatment_name_ipd	fingolimod	fingolimod	NA	FALSE	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s12325-014-0167-z	methodology	2	NA	treatment_name_nonipd	teriflunomide 7 mg	teriflunomide 7 mg	NA	FALSE	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s12325-014-0167-z	methodology	3	NA	treatment_name_ipd	fingolimod	fingolimod	NA	FALSE	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s12325-014-0167-z	methodology	3	NA	treatment_name_nonipd	teriflunomide 14 mg	teriflunomide 14 mg	NA	FALSE	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s12325-017-0564-1	methodology	1	NA	treatment_name_ipd	ibrutinib	ibrutinib	NA	FALSE	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1007/s12325-017-0564-1	methodology	1	NA	treatment_name_nonipd	obinutuzumab + chlorambucil	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-017-0564-1	methodology	1	NA	treatment_name_nonipd	obinutuzumab + chlorambucil	chlorambucil	NA	FALSE	L01AA02	ATC 5th	chlorambucil; oral	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1007/s12325-018-0734-9	methodology	1	NA	treatment_name_ipd	dabrafenib + trametinib	dabrafenib	NA	FALSE	L01EC02	ATC 5th	dabrafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors
10.1007/s12325-018-0734-9	methodology	1	NA	treatment_name_ipd	dabrafenib + trametinib	trametinib	NA	FALSE	L01EE01	ATC 5th	trametinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors
10.1007/s12325-018-0734-9	methodology	1	NA	treatment_name_nonipd	nivolumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-00991-w	methodology	1	NA	treatment_name_ipd	inotuzumab ozogamicin	inotuzumab ozogamicin	NA	FALSE	L01XC26	ATC 5th	inotuzumab ozogamicin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-00991-w	methodology	1	NA	treatment_name_nonipd	blinatumomab	blinatumomab	NA	FALSE	L01XC19	ATC 5th	blinatumomab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-00991-w	methodology	2	NA	treatment_name_ipd	inotuzumab ozogamicin	inotuzumab ozogamicin	NA	FALSE	L01XC26	ATC 5th	inotuzumab ozogamicin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-00991-w	methodology	2	NA	treatment_name_nonipd	blinatumomab	blinatumomab	NA	FALSE	L01XC19	ATC 5th	blinatumomab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-01156-5	methodology	1	NA	treatment_name_ipd	apalutamide	apalutamide	NA	FALSE	L02BB05	ATC 5th	apalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-019-01156-5	methodology	1	NA	treatment_name_nonipd	enzalutamide	enzalutamide	NA	FALSE	L02BB04	ATC 5th	enzalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-019-01157-4	methodology	1	NA	treatment_name_ipd	apalutamide	apalutamide	NA	FALSE	L02BB05	ATC 5th	apalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-019-01157-4	methodology	1	NA	treatment_name_nonipd	enzalutamide	enzalutamide	NA	FALSE	L02BB04	ATC 5th	enzalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-019-01173-4	methodology	1	NA	treatment_name_ipd	ratiofrequency catheter ablation with ablation index	ratiofrequency catheter ablation with ablation index	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1007/s12325-019-01173-4	methodology	1	NA	treatment_name_nonipd	ratiofrequency catheter ablation with cryoballoon	ratiofrequency catheter ablation with cryoballoon	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1007/s12325-019-0873-7	methodology	1	NA	treatment_name_ipd	blinatumomab	blinatumomab	NA	FALSE	L01XC19	ATC 5th	blinatumomab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-0873-7	methodology	1	NA	treatment_name_nonipd	inotuzumab ozogamicin	inotuzumab ozogamicin	NA	FALSE	L01XC26	ATC 5th	inotuzumab ozogamicin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-0873-7	methodology	2	NA	treatment_name_ipd	blinatumomab	blinatumomab	NA	FALSE	L01XC19	ATC 5th	blinatumomab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-019-0873-7	methodology	2	NA	treatment_name_nonipd	inotuzumab ozogamicin	inotuzumab ozogamicin	NA	FALSE	L01XC26	ATC 5th	inotuzumab ozogamicin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-020-01298-x	methodology	1	NA	treatment_name_ipd	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment	intravitreally administered aflibercept (ivt-afl) with 2 weeks adjustment	NA	FALSE	S01LA05	ATC 5th	aflibercept; ophthalmic	S	S01	S01L	S01LA	SENSORY ORGANS	OPHTHALMOLOGICALS	OCULAR VASCULAR DISORDER AGENTS	Antineovascularisation agents
10.1007/s12325-020-01298-x	methodology	1	NA	treatment_name_nonipd	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year followed by prorenata regimen in the second year	intravitreally administered aflibercept (ivt-afl) : one injection every 8 weeks in the first year	NA	FALSE	S01LA05	ATC 5th	aflibercept; ophthalmic	S	S01	S01L	S01LA	SENSORY ORGANS	OPHTHALMOLOGICALS	OCULAR VASCULAR DISORDER AGENTS	Antineovascularisation agents
10.1007/s12325-020-01378-y	methodology	1	NA	treatment_name_ipd	cabozantinib	cabozantinib	NA	FALSE	L01EX07	ATC 5th	L01EX07	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1007/s12325-020-01378-y	methodology	1	NA	treatment_name_nonipd	regorafenib	regorafenib	NA	FALSE	L01EX05	ATC 5th	L01EX05	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1007/s12325-020-01599-1	methodology	1	NA	treatment_name_ipd	recombinant fviiifc	recombinant fviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-020-01599-1	methodology	1	NA	treatment_name_nonipd	damoctocog alfa pegol (pooled prophylaxis)	damoctocog alfa pegol (pooled prophylaxis)	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-020-01599-1	methodology	2	NA	treatment_name_ipd	recombinant fviiifc	recombinant fviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-020-01599-1	methodology	2	NA	treatment_name_nonipd	damoctocog alfa pegol twice weekly	damoctocog alfa pegol twice weekly	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-020-01599-1	methodology	3	NA	treatment_name_ipd	recombinant fviiifc	recombinant fviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-020-01599-1	methodology	3	NA	treatment_name_nonipd	damoctocog alfa pegol q5d	damoctocog alfa pegol q5d	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-020-01599-1	methodology	4	NA	treatment_name_ipd	recombinant fviiifc	recombinant fviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-020-01599-1	methodology	4	NA	treatment_name_nonipd	damoctocog alfa pegol q7d	damoctocog alfa pegol q7d	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-021-01700-2	methodology	1	NA	treatment_name_ipd	cabozantinib	cabozantinib	NA	FALSE	L01EX07	ATC 5th	L01EX07	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1007/s12325-021-01700-2	methodology	1	NA	treatment_name_nonipd	ramucirumab	ramucirumab	NA	FALSE	L01XC21	ATC 5th	ramucirumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-021-01756-0	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel	lisocabtagene maraleucel	NA	TRUE	L01XL	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1007/s12325-021-01756-0	methodology	1	NA	treatment_name_nonipd	salvage chemotherapy	salvage chemotherapy	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.1007/s12325-021-01846-z	methodology	1	NA	treatment_name_ipd	thermocool smarttouch /thermocool smarttouch sf catheter with ai (stai)	thermocool smarttouch	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1007/s12325-021-01846-z	methodology	1	NA	treatment_name_nonipd	second-generation cryoballoon (cb)	second-generation cryoballoon (cb)	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1007/s12325-021-01853-0	methodology	1	NA	treatment_name_ipd	rviii-singlechain	rviii-singlechain	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-021-01853-0	methodology	1	NA	treatment_name_nonipd	rahf-pfm	rahf-pfm	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-021-01853-0	methodology	2	NA	treatment_name_ipd	rviii-singlechain	rviii-singlechain	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-021-01853-0	methodology	2	NA	treatment_name_nonipd	rahf-pfm	rahf-pfm	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-021-01853-0	methodology	3	NA	treatment_name_ipd	rviii-singlechain	rviii-singlechain	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-021-01853-0	methodology	3	NA	treatment_name_nonipd	rfviiifc	rfviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.1007/s12325-021-01884-7	methodology	1	NA	treatment_name_ipd	belantamab mafodotin	belantamab mafodotin	NA	FALSE	L01XC39	ATC 5th	belantamab mafodotin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-021-01884-7	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone	selinexor	NA	FALSE	L01XX66	ATC 5th	selinexor; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1007/s12325-021-01884-7	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_ipd	apalutamide + adt	apalutamide	NA	FALSE	L02BB05	ATC 5th	apalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_ipd	apalutamide + adt	adt	NA	FALSE	L02BB	ATC 4th	Anti-androgens	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_nonipd	darolutamide + adt	darolutamide	NA	FALSE	L02BB06	ATC 5th	darolutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-021-01885-6	methodology	1	NA	treatment_name_nonipd	darolutamide + adt	adt	NA	FALSE	L02BB	ATC 4th	Anti-androgens	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1007/s12325-022-02054-z	methodology	1	NA	treatment_name_ipd	tazemetostat	tazemetostat	NA	FALSE	L01XX72	ATC 5th	tazemetostat; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1007/s12325-022-02054-z	methodology	1	NA	treatment_name_nonipd	idelalisib	idelalisib	NA	FALSE	L01EM01	ATC 5th	idelalisib; oral	L	L01	L01E	L01EM	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Phosphatidylinositol-3-kinase (Pi3K) inhibitors
10.1007/s12325-022-02054-z	methodology	2	NA	treatment_name_ipd	tazemetostat	tazemetostat	NA	FALSE	L01XX72	ATC 5th	tazemetostat; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1007/s12325-022-02054-z	methodology	2	NA	treatment_name_nonipd	duvelisib	duvelisib	NA	FALSE	L01EM04	ATC 5th	duvelisib; oral	L	L01	L01E	L01EM	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Phosphatidylinositol-3-kinase (Pi3K) inhibitors
10.1007/s12325-022-02054-z	methodology	3	NA	treatment_name_ipd	tazemetostat	tazemetostat	NA	FALSE	L01XX72	ATC 5th	tazemetostat; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1007/s12325-022-02054-z	methodology	3	NA	treatment_name_nonipd	copanlisib	copanlisib	NA	FALSE	L01EM02	ATC 5th	copanlisib; oral	L	L01	L01E	L01EM	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Phosphatidylinositol-3-kinase (Pi3K) inhibitors
10.1007/s12325-022-02054-z	methodology	4	NA	treatment_name_ipd	tazemetostat	tazemetostat	NA	FALSE	L01XX72	ATC 5th	tazemetostat; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1007/s12325-022-02054-z	methodology	4	NA	treatment_name_nonipd	umbralisib	umbralisib	NA	FALSE	L01EX25	ATC 5th	umbralisib: oral	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1007/s12325-022-02099-0	methodology	1	NA	treatment_name_ipd	transarterial radioembolization	transarterial radioembolization	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1007/s12325-022-02099-0	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab	atezolizumab	NA	FALSE	L01XC32	ATC 5th	atezolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s12325-022-02099-0	methodology	1	NA	treatment_name_nonipd	atezolizumab + bevacizumab	bevacizumab	NA	FALSE	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1007/s13555-021-00646-1	methodology	1	NA	treatment_name_ipd	crisaborole ointment 2	crisaborole ointment 2	NA	FALSE	D11AH06	ATC 5th	crisaborole; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids
10.1007/s13555-021-00646-1	methodology	1	NA	treatment_name_nonipd	pimecrolimus 1	pimecrolimus 1	NA	FALSE	D11AH02	ATC 5th	pimecrolimus; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids
10.1007/s13555-021-00646-1	methodology	2	NA	treatment_name_ipd	crisaborole	crisaborole	NA	FALSE	D11AH06	ATC 5th	crisaborole; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids
10.1007/s13555-021-00646-1	methodology	2	NA	treatment_name_nonipd	tacrolimus 0.03	tacrolimus 0.03	NA	FALSE	D11AH01	ATC 5th	tacrolimus; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_ipd	panobinostat + bortezomib + dexamethasone	panobinostat	NA	FALSE	L01XH03	ATC 5th	panobinostat; oral	L	L01	L01X	L01XH	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Histone deacetylase (HDAC) inhibitors
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_ipd	panobinostat + bortezomib + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_ipd	panobinostat + bortezomib + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_nonipd	lenalidomide + dexamethasone	lenalidomide	NA	FALSE	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1007/s40258-016-0271-0	methodology	1	NA	treatment_name_nonipd	lenalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1007/s40263-013-0102-x	methodology	1	NA	treatment_name_ipd	guanfacine extended release	guanfacine extended release	NA	FALSE	C02AC02	ATC 5th	guanfacine; oral	C	C02	C02A	C02AC	CARDIOVASCULAR SYSTEM	ANTIHYPERTENSIVES	ANTIADRENERGIC AGENTS, CENTRALLY ACTING	Imidazoline receptor agonists
10.1007/s40263-013-0102-x	methodology	1	NA	treatment_name_nonipd	atomoxetine	atomoxetine	NA	FALSE	N06BA09	ATC 5th	atomoxetine; oral	N	N06	N06B	N06BA	NERVOUS SYSTEM	PSYCHOANALEPTICS	PSYCHOSTIMULANTS, AGENTS USED FOR ADHD AND NOOTROPICS	Centrally acting sympathomimetics
10.1007/s40263-019-00672-w	methodology	1	NA	treatment_name_ipd	brexanolone	brexanolone	NA	FALSE	N06AX29	NA	NA	N	N06	N06A	N06AX	NERVOUS SYSTEM	PSYCHOANALEPTICS	ANTIDEPRESSANTS	OTHER ANTIDEPRESSANTS
10.1007/s40263-019-00672-w	methodology	1	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1007/s40263-021-00805-0	methodology	1	NA	treatment_name_ipd	ozanimod	ozanimod	NA	FALSE	L04AA38	ATC 5th	ozanimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s40263-021-00805-0	methodology	1	NA	treatment_name_nonipd	dimethyl fumarate	dimethyl fumarate	NA	FALSE	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1007/s40273-021-01015-8	methodology	1	NA	treatment_name_ipd	lorlatinib	lorlatinib	NA	FALSE	L01ED05	ATC 5th	lorlatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1007/s40273-021-01015-8	methodology	1	NA	treatment_name_nonipd	pemetrexed or docetaxel	pemetrexed	NA	FALSE	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.1007/s40273-021-01015-8	methodology	1	NA	treatment_name_nonipd	pemetrexed or docetaxel	docetaxel	NA	FALSE	L01CD02	ATC 5th	docetaxel; parenteral	L	L01	L01C	L01CD	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Taxanes
10.1007/s40273-021-01015-8	methodology	2	NA	treatment_name_ipd	lorlatinib	lorlatinib	NA	FALSE	L01ED05	ATC 5th	lorlatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1007/s40273-021-01015-8	methodology	2	NA	treatment_name_nonipd	systemic therapy	systemic therapy	supportive or standard of care	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1007/s40744-017-0070-6	methodology	1	NA	treatment_name_ipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.1007/s40744-017-0070-6	methodology	1	NA	treatment_name_nonipd	secukinumab 150 mg	secukinumab 150 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1007/s40744-017-0070-6	methodology	2	NA	treatment_name_ipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.1007/s40744-017-0070-6	methodology	2	NA	treatment_name_nonipd	secukinumab 300 mg	secukinumab 300 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1007/s40744-018-0106-6	methodology	1	NA	treatment_name_ipd	secukinumab 150 mg	secukinumab 150 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1007/s40744-018-0106-6	methodology	1	NA	treatment_name_nonipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.1007/s40744-018-0106-6	methodology	2	NA	treatment_name_ipd	secukinumab 300 mg	secukinumab 300 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1007/s40744-018-0106-6	methodology	2	NA	treatment_name_nonipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.1007/s40744-018-0106-6	methodology	3	NA	treatment_name_ipd	secukinumab 150 mg	secukinumab 150 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1007/s40744-018-0106-6	methodology	3	NA	treatment_name_nonipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.1007/s40744-018-0106-6	methodology	4	NA	treatment_name_ipd	secukinumab 300 mg	secukinumab 300 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1007/s40744-018-0106-6	methodology	4	NA	treatment_name_nonipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.1007/s40744-020-00257-w	methodology	1	NA	treatment_name_ipd	upadacitinib monotherapy	upadacitinib monotherapy	NA	FALSE	L04AA44	ATC 5th	upadacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s40744-020-00257-w	methodology	1	NA	treatment_name_nonipd	tofacitinib + methotrexate	tofacitinib	NA	FALSE	L04AA29	ATC 5th	tofacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s40744-020-00257-w	methodology	1	NA	treatment_name_nonipd	tofacitinib + methotrexate	methotrexate	NA	FALSE	L01BA01	ATC 5th	methotrexate; systemic (folic acid analog.)	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_ipd	upadacitinib + methotrexate	upadacitinib	NA	FALSE	L04AA44	ATC 5th	upadacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_ipd	upadacitinib + methotrexate	methotrexate	NA	FALSE	L01BA01	ATC 5th	methotrexate; systemic (folic acid analog.)	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_nonipd	tofacitinib + methotrexate	tofacitinib	NA	FALSE	L04AA29	ATC 5th	tofacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1007/s40744-020-00257-w	methodology	2	NA	treatment_name_nonipd	tofacitinib + methotrexate	methotrexate	NA	FALSE	L01BA01	ATC 5th	methotrexate; systemic (folic acid analog.)	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.1016/j.bbmt.2020.06.008	methodology	1	NA	treatment_name_ipd	axicabtagene ciloleucel	axicabtagene ciloleucel	NA	TRUE	L01XX70	ATC 5th	axicabtagene ciloleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1016/j.bbmt.2020.06.008	methodology	1	NA	treatment_name_nonipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1016/j.clgc.2020.07.006	methodology	1	NA	treatment_name_ipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.clgc.2020.07.006	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine	carboplatin	NA	FALSE	L01XA02	ATC 5th	carboplatin; inhalant, parenteral	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds
10.1016/j.clgc.2020.07.006	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine	gemcitabine	NA	FALSE	L01BC05	ATC 5th	gemcitabine; parenteral	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.1016/j.clinthera.2015.09.013	methodology	1	NA	treatment_name_ipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1016/j.clinthera.2015.09.013	methodology	1	NA	treatment_name_nonipd	axitinib	axitinib	NA	FALSE	L01EK01	ATC 5th	axitinib; oral	L	L01	L01E	L01EK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir	sofosbuvir	NA	FALSE	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin	sofosbuvir	NA	FALSE	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1016/j.clinthera.2015.12.017	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1016/j.clinthera.2017.08.010	methodology	1	NA	treatment_name_ipd	pomalidomide + dexamethasone	pomalidomide	NA	FALSE	L04AX06	ATC 5th	pomalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1016/j.clinthera.2017.08.010	methodology	1	NA	treatment_name_ipd	pomalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1016/j.clinthera.2017.08.010	methodology	1	NA	treatment_name_nonipd	daratumumab	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.clinthera.2017.08.010	methodology	2	NA	treatment_name_ipd	pomalidomide + dexamethasone	pomalidomide	NA	FALSE	L04AX06	ATC 5th	pomalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1016/j.clinthera.2017.08.010	methodology	2	NA	treatment_name_ipd	pomalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1016/j.clinthera.2017.08.010	methodology	2	NA	treatment_name_nonipd	carfilzomib	carfilzomib	NA	FALSE	L01XG02	ATC 5th	carfilzomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1016/j.clinthera.2019.09.012	methodology	1	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	1	NA	treatment_name_nonipd	ibrutinib	ibrutinib	NA	FALSE	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	2	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	2	NA	treatment_name_nonipd	bortezomib	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1016/j.clinthera.2019.09.012	methodology	3	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	3	NA	treatment_name_nonipd	lenalidomide	lenalidomide	NA	FALSE	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1016/j.clinthera.2019.09.012	methodology	4	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	4	NA	treatment_name_nonipd	temsirolimus	temsirolimus	NA	FALSE	L01EG01	ATC 5th	temsirolimus; parenteral	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1016/j.clinthera.2019.09.012	methodology	5	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	5	NA	treatment_name_nonipd	ibrutinib + rituximab	ibrutinib	NA	FALSE	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	5	NA	treatment_name_nonipd	ibrutinib + rituximab	rituximab	NA	FALSE	L01XC02	ATC 5th	rituximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.clinthera.2019.09.012	methodology	6	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	6	NA	treatment_name_nonipd	bendamustine + rituximab	bendamustine	NA	FALSE	L01AA09	ATC 5th	bendamustine; parenteral	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1016/j.clinthera.2019.09.012	methodology	6	NA	treatment_name_nonipd	bendamustine + rituximab	rituximab	NA	FALSE	L01XC02	ATC 5th	rituximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.clinthera.2019.09.012	methodology	7	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1016/j.clinthera.2019.09.012	methodology	7	NA	treatment_name_nonipd	lenalidomide + rituximab	lenalidomide	NA	FALSE	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1016/j.clinthera.2019.09.012	methodology	7	NA	treatment_name_nonipd	lenalidomide + rituximab	rituximab	NA	FALSE	L01XC02	ATC 5th	rituximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	treatment_name_ipd	[177lu]lu-dota-tate	[177lu]lu-dota-tate	NA	FALSE	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals
10.1016/j.ejcsup.2021.06.002	methodology	1	NA	treatment_name_nonipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	treatment_name_ipd	[177lu]lu-dota-tate	[177lu]lu-dota-tate	NA	FALSE	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals
10.1016/j.ejcsup.2021.06.002	methodology	2	NA	treatment_name_nonipd	best supportive care (bsc)	best supportive care (bsc)	supportive or standard of care	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	treatment_name_ipd	[177lu]lu-dota-tate	[177lu]lu-dota-tate	NA	FALSE	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals
10.1016/j.ejcsup.2021.06.002	methodology	3	NA	treatment_name_nonipd	sunitinib	sunitinib	NA	FALSE	L01EX01	ATC 5th	L01EX01	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	treatment_name_ipd	[177lu]lu-dota-tate	[177lu]lu-dota-tate	NA	FALSE	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals
10.1016/j.ejcsup.2021.06.002	methodology	4	NA	treatment_name_nonipd	best supportive care	best supportive care	supportive or standard of care	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	treatment_name_ipd	[177lu]lu-dota-tate	[177lu]lu-dota-tate	NA	FALSE	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals
10.1016/j.ejcsup.2021.06.002	methodology	5	NA	treatment_name_nonipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	treatment_name_ipd	[177lu]lu-dota-tate	[177lu]lu-dota-tate	NA	FALSE	V10XX04	ATC 5th	lutetium (177Lu) oxodotreotide; parenteral	V	V10	V10X	V10XX	VARIOUS	THERAPEUTIC RADIOPHARMACEUTICALS	OTHER THERAPEUTIC RADIOPHARMACEUTICALS	Various therapeutic radiopharmaceuticals
10.1016/j.ejcsup.2021.06.002	methodology	6	NA	treatment_name_nonipd	best supportive care	best supportive care	supportive or standard of care	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib	dabrafenib	NA	FALSE	L01EC02	ATC 5th	dabrafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors
10.1016/j.esmoop.2021.100050	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib	trametinib	NA	FALSE	L01EE01	ATC 5th	trametinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_nonipd	encorafenib + binimetinib	encorafenib	NA	FALSE	L01EC03	ATC 5th	encorafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors
10.1016/j.esmoop.2021.100050	methodology	2	NA	treatment_name_nonipd	encorafenib + binimetinib	binimetinib	NA	FALSE	L01EE03	ATC 5th	binimetinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_ipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_ipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_nonipd	vemurafenib + cobimetinib	vemurafenib	NA	FALSE	L01EC01	ATC 5th	vemurafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors
10.1016/j.esmoop.2021.100050	methodology	3	NA	treatment_name_nonipd	vemurafenib + cobimetinib	cobimetinib	NA	FALSE	L01EE02	ATC 5th	cobimetinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors
10.1016/j.euo.2018.09.009	methodology	1	NA	treatment_name_ipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.euo.2018.09.009	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine	carboplatin	NA	FALSE	L01XA02	ATC 5th	carboplatin; inhalant, parenteral	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds
10.1016/j.euo.2018.09.009	methodology	1	NA	treatment_name_nonipd	carboplatin + gemcitabine	gemcitabine	NA	FALSE	L01BC05	ATC 5th	gemcitabine; parenteral	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.1016/j.euo.2018.09.009	methodology	2	NA	treatment_name_ipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.euo.2018.09.009	methodology	2	NA	treatment_name_nonipd	gemcitabine	gemcitabine	NA	FALSE	L01BC05	ATC 5th	gemcitabine; parenteral	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.1016/j.jtho.2016.05.029	methodology	1	NA	treatment_name_ipd	ceritinib	ceritinib	NA	FALSE	L01ED02	ATC 5th	ceritinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1016/j.jtho.2016.05.029	methodology	1	NA	treatment_name_nonipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1016/j.jval.2018.03.015	methodology	1	NA	treatment_name_ipd	magnetic resonance-guided focused ultrasound	magnetic resonance-guided focused ultrasound	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1016/j.jval.2018.03.015	methodology	1	NA	treatment_name_nonipd	unilateral deep brain stimulation	unilateral deep brain stimulation	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	treatment_name_ipd	magnetic resonance-guided focused ultrasound	magnetic resonance-guided focused ultrasound	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1016/j.jval.2018.03.015	methodology	2	NA	treatment_name_nonipd	unilateral deep brain stimulation (dbs)	unilateral deep brain stimulation (dbs)	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy	chemotherapy	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_nonipd	atezolizumab + chemotherapy	atezolizumab	NA	FALSE	L01XC32	ATC 5th	atezolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.lungcan.2021.03.020	methodology	1	NA	treatment_name_nonipd	atezolizumab + chemotherapy	chemotherapy	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_ipd	pembrolizumab + chemotherapy	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_ipd	pembrolizumab + chemotherapy	chemotherapy	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_nonipd	atezolizumab + bevacizumab + chemotherapy	atezolizumab	NA	FALSE	L01XC32	ATC 5th	atezolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_nonipd	atezolizumab + bevacizumab + chemotherapy	bevacizumab	NA	FALSE	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1016/j.lungcan.2021.03.020	methodology	2	NA	treatment_name_nonipd	atezolizumab + bevacizumab + chemotherapy	chemotherapy	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.1016/j.msard.2021.102972	methodology	1	NA	treatment_name_ipd	ozanimod	ozanimod	NA	FALSE	L04AA38	ATC 5th	ozanimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1016/j.msard.2021.102972	methodology	1	NA	treatment_name_nonipd	teriflunomide	teriflunomide	NA	FALSE	L04AA31	ATC 5th	teriflunomide; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2016.1248380	methodology	1	NA	treatment_name_ipd	dimethyl fumarate	dimethyl fumarate	NA	FALSE	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1080/03007995.2016.1248380	methodology	1	NA	treatment_name_nonipd	fingolimod	fingolimod	NA	FALSE	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2018.1510225	methodology	1	NA	treatment_name_ipd	ponatinib	ponatinib	NA	FALSE	L01EA05	ATC 5th	ponatinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2018.1510225	methodology	1	NA	treatment_name_nonipd	bosutinib	bosutinib	NA	FALSE	L01EA04	ATC 5th	bosutinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2018.1520696	methodology	1	NA	treatment_name_ipd	brigatinib	brigatinib	NA	FALSE	L01ED04	ATC 5th	brigatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1520696	methodology	1	NA	treatment_name_nonipd	ceritinib	ceritinib	NA	FALSE	L01ED02	ATC 5th	ceritinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1520696	methodology	2	NA	treatment_name_ipd	brigatinib	brigatinib	NA	FALSE	L01ED04	ATC 5th	brigatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1520696	methodology	2	NA	treatment_name_nonipd	ceritinib	ceritinib	NA	FALSE	L01ED02	ATC 5th	ceritinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1520696	methodology	3	NA	treatment_name_ipd	brigatinib	brigatinib	NA	FALSE	L01ED04	ATC 5th	brigatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1520696	methodology	3	NA	treatment_name_nonipd	alectinib	alectinib	NA	FALSE	L01ED03	ATC 5th	alectinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1520696	methodology	4	NA	treatment_name_ipd	brigatinib	brigatinib	NA	FALSE	L01ED04	ATC 5th	brigatinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1520696	methodology	4	NA	treatment_name_nonipd	alectinib	alectinib	NA	FALSE	L01ED03	ATC 5th	alectinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1541443	methodology	1	NA	treatment_name_ipd	ceritinib	ceritinib	NA	FALSE	L01ED02	ATC 5th	ceritinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2018.1541443	methodology	1	NA	treatment_name_nonipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/03007995.2019.1585779	methodology	1	NA	treatment_name_ipd	cladribine	cladribine	NA	FALSE	L01BB04	ATC 5th	cladribine; systemic	L	L01	L01B	L01BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Purine analogues
10.1080/03007995.2019.1585779	methodology	1	NA	treatment_name_nonipd	alemtuzumab	alemtuzumab	NA	FALSE	L04AA34	ATC 5th	alemtuzumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2019.1605239	methodology	1	NA	treatment_name_ipd	bosutinib	bosutinib	NA	FALSE	L01EA04	ATC 5th	bosutinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2019.1605239	methodology	1	NA	treatment_name_nonipd	dasatinib	dasatinib	NA	FALSE	L01EA02	ATC 5th	dasatinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2019.1605239	methodology	2	NA	treatment_name_ipd	bosutinib	bosutinib	NA	FALSE	L01EA04	ATC 5th	bosutinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2019.1605239	methodology	2	NA	treatment_name_nonipd	nilotinib	nilotinib	NA	FALSE	L01EA03	ATC 5th	nilotinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2020.1747999	methodology	1	NA	treatment_name_ipd	siponimod	siponimod	NA	FALSE	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	1	NA	treatment_name_nonipd	ifn-1b 250 g once every other day (q2d)	ifn-1b 250 g once every other day (q2d)	NA	FALSE	L03AB08	ATC 5th	interferon beta-1b; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1080/03007995.2020.1747999	methodology	2	NA	treatment_name_ipd	siponimod	siponimod	NA	FALSE	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	2	NA	treatment_name_nonipd	ifn-1a 22 g once weekly (qw)	ifn-1a 22 g once weekly (qw)	NA	FALSE	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1080/03007995.2020.1747999	methodology	3	NA	treatment_name_ipd	siponimod	siponimod	NA	FALSE	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	3	NA	treatment_name_nonipd	natalizumab	natalizumab	NA	FALSE	L04AA23	ATC 5th	natalizumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	4	NA	treatment_name_ipd	siponimod	siponimod	NA	FALSE	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	4	NA	treatment_name_nonipd	sc ifn-1a 22 g three times weekly	sc ifn-1a 22 g three times weekly	NA	FALSE	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1080/03007995.2020.1747999	methodology	5	NA	treatment_name_ipd	siponimod	siponimod	NA	FALSE	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	5	NA	treatment_name_nonipd	sc ifn-1a 44 g three times weekly	sc ifn-1a 44 g three times weekly	NA	FALSE	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1080/03007995.2020.1747999	methodology	6	NA	treatment_name_ipd	siponimod	siponimod	NA	FALSE	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	6	NA	treatment_name_nonipd	ifn-1b 8 miu once every other day	ifn-1b 8 miu once every other day	NA	FALSE	L03AB08	ATC 5th	interferon beta-1b; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1080/03007995.2020.1747999	methodology	7	NA	treatment_name_ipd	siponimod	siponimod	NA	FALSE	L04AA42	ATC 5th	siponimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2020.1747999	methodology	7	NA	treatment_name_nonipd	im ifn-1a 60 g once weekly	im ifn-1a 60 g once weekly	NA	FALSE	L03AB07	ATC 5th	interferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1080/03007995.2021.1896489	methodology	1	NA	treatment_name_ipd	bosutinib	bosutinib	NA	FALSE	L01EA04	ATC 5th	bosutinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2021.1896489	methodology	1	NA	treatment_name_nonipd	nilotinib	nilotinib	NA	FALSE	L01EA03	ATC 5th	nilotinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2021.1896489	methodology	2	NA	treatment_name_ipd	bosutinib	bosutinib	NA	FALSE	L01EA04	ATC 5th	bosutinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2021.1896489	methodology	2	NA	treatment_name_nonipd	dasatinib	dasatinib	NA	FALSE	L01EA02	ATC 5th	dasatinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1080/03007995.2021.1947216	methodology	1	NA	treatment_name_ipd	onasemnogene abeparvovec	onasemnogene abeparvovec	NA	FALSE	M09AX09	ATC 5th	onasemnogene abeparvovec; parenteral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.1080/03007995.2021.1947216	methodology	1	NA	treatment_name_nonipd	nusinersen	nusinersen	NA	FALSE	M09AX07	ATC 5th	nusinersen; systemic	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.1080/03007995.2021.1953456	methodology	1	NA	treatment_name_ipd	ciltacabtagene autoleucel	ciltacabtagene autoleucel	NA	TRUE	L01XL05	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1080/03007995.2021.1953456	methodology	1	NA	treatment_name_nonipd	idecabtagene vicleucel	idecabtagene vicleucel	NA	TRUE	L01XL07	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1080/03007995.2021.1971182	methodology	1	NA	treatment_name_ipd	pegcetacoplan	pegcetacoplan	NA	FALSE	L04AA54	NA	NA	L	L04	L04A	L04AA	NERVOUS ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2021.1971182	methodology	1	NA	treatment_name_nonipd	ravulizumab	ravulizumab	NA	FALSE	L04AA43	ATC 5th	ravulizumab; parenteral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1080/03007995.2022.2030112	methodology	1	NA	treatment_name_ipd	amlodipine 5 mg + bisoprolol 5 mg	amlodipine 5 mg	NA	FALSE	C08CA01	ATC 5th	amlodipine; oral	C	C08	C08C	C08CA	CARDIOVASCULAR SYSTEM	CALCIUM CHANNEL BLOCKERS	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	Dihydropyridine derivatives
10.1080/03007995.2022.2030112	methodology	1	NA	treatment_name_ipd	amlodipine 5 mg + bisoprolol 5 mg	bisoprolol 5 mg	NA	FALSE	C07AB07	ATC 5th	bisoprolol; oral	C	C07	C07A	C07AB	CARDIOVASCULAR SYSTEM	BETA BLOCKING AGENTS	BETA BLOCKING AGENTS	Beta blocking agents, selective
10.1080/03007995.2022.2030112	methodology	1	NA	treatment_name_nonipd	amlodipine 10mg,	amlodipine 10mg,	NA	FALSE	C08CA01	ATC 5th	amlodipine; oral	C	C08	C08C	C08CA	CARDIOVASCULAR SYSTEM	CALCIUM CHANNEL BLOCKERS	SELECTIVE CALCIUM CHANNEL BLOCKERS WITH MAINLY VASCULAR EFFECTS	Dihydropyridine derivatives
10.1080/09546634.2020.1747592	methodology	1	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	1	NA	treatment_name_nonipd	guselkumab	guselkumab	NA	FALSE	L04AC16	ATC 5th	guselkumab; systemic	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	2	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	2	NA	treatment_name_nonipd	tildrakizumab 100mg	tildrakizumab 100mg	NA	FALSE	L04AC17	ATC 5th	tildrakizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	3	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	3	NA	treatment_name_nonipd	tildrakizumab 200mg	tildrakizumab 200mg	NA	FALSE	L04AC17	ATC 5th	tildrakizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	4	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	4	NA	treatment_name_nonipd	tildrakizumab 100mg	tildrakizumab 100mg	NA	FALSE	L04AC17	ATC 5th	tildrakizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	5	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	5	NA	treatment_name_nonipd	tildrakizumab 200mg	tildrakizumab 200mg	NA	FALSE	L04AC17	ATC 5th	tildrakizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	6	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	6	NA	treatment_name_nonipd	risankizumab	risankizumab	NA	FALSE	L04AC18	ATC 5th	risankizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	7	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/09546634.2020.1747592	methodology	7	NA	treatment_name_nonipd	risankizumab	risankizumab	NA	FALSE	L04AC18	ATC 5th	risankizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_ipd	vmp (bortezomib/melphalan/prednisone)	vmp (bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_ipd	vmp (bortezomib/melphalan/prednisone)	vmp (bortezomib	NA	FALSE	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_ipd	vmp (bortezomib/melphalan/prednisone)	vmp (bortezomib	NA	FALSE	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_ipd	vmp (bortezomib/melphalan/prednisone)	melphalan	NA	FALSE	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_nonipd	modified vmp schedule	modified vmp schedule	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_nonipd	modified vmp schedule	modified vmp schedule	NA	FALSE	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1080/10428194.2019.1675881	methodology	1	NA	treatment_name_nonipd	modified vmp schedule	modified vmp schedule	NA	FALSE	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_nonipd	lenalidomide-dexamethasone continuous	lenalidomide-dexamethasone continuous	NA	FALSE	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1080/10428194.2019.1682571	methodology	1	NA	treatment_name_nonipd	lenalidomide-dexamethasone continuous	lenalidomide-dexamethasone continuous	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_nonipd	lenalidomide-dexamethasone 18 months (rd18)	lenalidomide-dexamethasone 18 months (rd18)	NA	FALSE	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1080/10428194.2019.1682571	methodology	2	NA	treatment_name_nonipd	lenalidomide-dexamethasone 18 months (rd18)	lenalidomide-dexamethasone 18 months (rd18)	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_ipd	daratumumab-bortezomib-melphalan-prednisone	daratumumab-bortezomib-melphalan-prednisone	NA	FALSE	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_nonipd	melphalan-prednisone-thalidomide	melphalan-prednisone-thalidomide	NA	FALSE	L01AA03	ATC 5th	melphalan; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_nonipd	melphalan-prednisone-thalidomide	melphalan-prednisone-thalidomide	NA	FALSE	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1080/10428194.2019.1682571	methodology	3	NA	treatment_name_nonipd	melphalan-prednisone-thalidomide	melphalan-prednisone-thalidomide	NA	FALSE	H02AB07	ATC 5th	prednisone; oral	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2021.1913143	methodology	1	NA	treatment_name_ipd	idecabtagene vicleucel	idecabtagene vicleucel	NA	TRUE	L01XL07	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1080/10428194.2021.1913143	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone	selinexor	NA	FALSE	L01XX66	ATC 5th	selinexor; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1080/10428194.2021.1913143	methodology	1	NA	treatment_name_nonipd	selinexor + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2021.1913143	methodology	2	NA	treatment_name_ipd	idecabtagene + vicleucel	idecabtagene	NA	TRUE	L01XL07	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1080/10428194.2021.1913143	methodology	2	NA	treatment_name_ipd	idecabtagene + vicleucel	vicleucel	NA	TRUE	L01XL07	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1080/10428194.2021.1913143	methodology	2	NA	treatment_name_nonipd	belantamab mafodotin	belantamab mafodotin	NA	FALSE	L01XC39	ATC 5th	belantamab mafodotin; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.1913144	methodology	1	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	1	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.1913144	methodology	1	NA	treatment_name_nonipd	ibrutinib	ibrutinib	NA	FALSE	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	2	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	2	NA	treatment_name_nonipd	ibrutinib	ibrutinib	NA	FALSE	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_nonipd	ibrutinib + obinutuzumab	ibrutinib	NA	FALSE	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	3	NA	treatment_name_nonipd	ibrutinib + obinutuzumab	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.1913144	methodology	4	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	4	NA	treatment_name_nonipd	ibrutinib + obinutuzumab	ibrutinib	NA	FALSE	L01EL01	ATC 5th	ibrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	4	NA	treatment_name_nonipd	ibrutinib + obinutuzumab	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_ipd	acalabrutinib + obinutuzumab	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_nonipd	venetoclax + obinutuzumab	venetoclax	NA	FALSE	L01XX52	ATC 5th	venetoclax; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1080/10428194.2021.1913144	methodology	5	NA	treatment_name_nonipd	venetoclax + obinutuzumab	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.1913144	methodology	6	NA	treatment_name_ipd	acalabrutinib	acalabrutinib	NA	FALSE	L01EL02	ATC 5th	acalabrutinib; oral	L	L01	L01E	L01EL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bruton's tyrosine kinase (BTK) inhibitors
10.1080/10428194.2021.1913144	methodology	6	NA	treatment_name_nonipd	venetoclax + obinutuzumab	venetoclax	NA	FALSE	L01XX52	ATC 5th	venetoclax; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1080/10428194.2021.1913144	methodology	6	NA	treatment_name_nonipd	venetoclax + obinutuzumab	obinutuzumab	NA	FALSE	L01XC15	ATC 5th	obinutuzumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2021.2010069	methodology	1	NA	treatment_name_ipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1080/10428194.2021.2010069	methodology	1	NA	treatment_name_nonipd	lisocabtagene	lisocabtagene	NA	TRUE	L01XL	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_ipd	carfizomib + dexamethasone+daratumumab	carfizomib	NA	FALSE	L01XG02	ATC 5th	carfilzomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_ipd	carfizomib + dexamethasone+daratumumab	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_ipd	carfizomib + dexamethasone+daratumumab	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_nonipd	daratumumab + velcade+dexamethasone	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_nonipd	daratumumab + velcade+dexamethasone	velcade	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.1080/10428194.2022.2047962	methodology	1	NA	treatment_name_nonipd	daratumumab + velcade+dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1080/13696998.2018.1443111	methodology	1	NA	treatment_name_ipd	ceritinib	ceritinib	NA	FALSE	L01ED02	ATC 5th	ceritinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/13696998.2018.1443111	methodology	1	NA	treatment_name_nonipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_ipd	calcipotriene 0.005/betamethasone dipropionate 0.064% foam	calcipotriene 0.005	NA	FALSE	D05AX02	ATC 5th	calcipotriol; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_ipd	calcipotriene 0.005/betamethasone dipropionate 0.064% foam	betamethasone dipropionate 0.064% foam	NA	FALSE	D07XC01	ATC 5th	betamethasone, combinations; topical	D	D07	D07X	D07XC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, OTHER COMBINATIONS	Corticosteroids, potent, other combinations
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_nonipd	halobetasol 0.01/tazarotene 0.045%	halobetasol 0.01	NA	FALSE	D07AC21	ATC 5th	ulobetasol; topical	D	D07	D07A	D07AC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, PLAIN	Corticosteroids, potent (group III)
10.1080/13696998.2020.1722139	methodology	1	NA	treatment_name_nonipd	halobetasol 0.01/tazarotene 0.045%	tazarotene 0.045%	NA	FALSE	D05AX05	ATC 5th	tazarotene; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use
10.1080/14656566.2020.1811850	methodology	1	NA	treatment_name_ipd	patisiran	patisiran	NA	FALSE	N07XX12	ATC 5th	patisiran; parenteral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs
10.1080/14656566.2020.1811850	methodology	1	NA	treatment_name_nonipd	inotersen	inotersen	NA	FALSE	N07XX15	ATC 5th	inotersen; parenteral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs
10.1080/14760584.2021.1994858	methodology	1	NA	treatment_name_ipd	15-valent pneumococcal conjugate vaccine	15-valent pneumococcal conjugate vaccine	NA	FALSE	J07AL	ATC 4th	Pneumococcal vaccines	J	J07	J07A	J07AL	ANTIINFECTIVES FOR SYSTEMIC USE	VACCINES	BACTERIAL VACCINES	Pneumococcal vaccines
10.1080/14760584.2021.1994858	methodology	1	NA	treatment_name_nonipd	20-valent pneumococcal conjugate vaccine	20-valent pneumococcal conjugate vaccine	NA	FALSE	J07AL	ATC 4th	Pneumococcal vaccines	J	J07	J07A	J07AL	ANTIINFECTIVES FOR SYSTEMIC USE	VACCINES	BACTERIAL VACCINES	Pneumococcal vaccines
10.1080/17474086.2018.1475226	methodology	1	NA	treatment_name_ipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1080/17474086.2018.1475226	methodology	1	NA	treatment_name_nonipd	st + ard of care	ard of care	supportive or standard of care	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1093/europace/euy160	methodology	1	NA	treatment_name_ipd	rivaroxaban	rivaroxaban	NA	FALSE	B01AF01	ATC 5th	rivaroxaban; oral	B	B01	B01A	B01AF	BLOOD AND BLOOD FORMING ORGANS	ANTITHROMBOTIC AGENTS	ANTITHROMBOTIC AGENTS	Direct factor Xa inhibitors
10.1093/europace/euy160	methodology	1	NA	treatment_name_nonipd	rivaroxaban	rivaroxaban	NA	FALSE	B01AF01	ATC 5th	rivaroxaban; oral	B	B01	B01A	B01AF	BLOOD AND BLOOD FORMING ORGANS	ANTITHROMBOTIC AGENTS	ANTITHROMBOTIC AGENTS	Direct factor Xa inhibitors
10.1093/jnci/djab071	methodology	1	NA	treatment_name_ipd	abiraterone acetate	abiraterone acetate	NA	FALSE	L02BX03	ATC 5th	abiraterone; oral	L	L02	L02B	L02BX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Other hormone antagonists and related agents
10.1093/jnci/djab071	methodology	1	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1097/brs.0000000000002647	methodology	1	NA	treatment_name_ipd	total disc replacement	total disc replacement	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1097/brs.0000000000002647	methodology	1	NA	treatment_name_nonipd	fusion	fusion	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1097/ju.0000000000001767	methodology	1	NA	treatment_name_ipd	darolutamide	darolutamide	NA	FALSE	L02BB06	ATC 5th	darolutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1097/ju.0000000000001767	methodology	1	NA	treatment_name_nonipd	apalutamide	apalutamide	NA	FALSE	L02BB05	ATC 5th	apalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1097/ju.0000000000001767	methodology	2	NA	treatment_name_ipd	darolutamide	darolutamide	NA	FALSE	L02BB06	ATC 5th	darolutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1097/ju.0000000000001767	methodology	2	NA	treatment_name_nonipd	enzalutamide	enzalutamide	NA	FALSE	L02BB04	ATC 5th	enzalutamide; oral	L	L02	L02B	L02BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-androgens
10.1111/bjd.16140	methodology	3	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1111/bjd.16140	methodology	3	NA	treatment_name_nonipd	secukinumab	secukinumab	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1111/bjd.16140	methodology	5	NA	treatment_name_ipd	ixekizumab	ixekizumab	NA	FALSE	L04AC13	ATC 5th	ixekizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1111/bjd.16140	methodology	5	NA	treatment_name_nonipd	secukinumab	secukinumab	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1111/cea.13561	methodology	1	NA	treatment_name_ipd	benralizumab	benralizumab	NA	FALSE	R03DX10	ATC 5th	benralizumab; systemic	R	R03	R03D	R03DX	RESPIRATORY SYSTEM	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	Other systemic drugs for obstructive airway diseases
10.1111/cea.13561	methodology	1	NA	treatment_name_nonipd	mepolizumab	mepolizumab	NA	FALSE	R03DX09	ATC 5th	mepolizumab; parenteral	R	R03	R03D	R03DX	RESPIRATORY SYSTEM	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	Other systemic drugs for obstructive airway diseases
10.1111/cea.13561	methodology	2	NA	treatment_name_ipd	benralizumab	benralizumab	NA	FALSE	R03DX10	ATC 5th	benralizumab; systemic	R	R03	R03D	R03DX	RESPIRATORY SYSTEM	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	Other systemic drugs for obstructive airway diseases
10.1111/cea.13561	methodology	2	NA	treatment_name_nonipd	dupilumab	dupilumab	NA	FALSE	D11AH05	ATC 5th	dupilumab; topical	D	D11	D11A	D11AH	DERMATOLOGICALS	OTHER DERMATOLOGICAL PREPARATIONS	OTHER DERMATOLOGICAL PREPARATIONS	Agents for dermatitis, excluding corticosteroids
10.1111/dom.14497	methodology	1	NA	treatment_name_ipd	semaglutide 1.0mg	semaglutide 1.0mg	NA	FALSE	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1111/dom.14497	methodology	1	NA	treatment_name_nonipd	dulaglutide 3.0mg	dulaglutide 3.0mg	NA	FALSE	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1111/dom.14497	methodology	2	NA	treatment_name_ipd	semaglutide 1.0mg	semaglutide 1.0mg	NA	FALSE	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1111/dom.14497	methodology	2	NA	treatment_name_nonipd	dulaglutide 4.5mg	dulaglutide 4.5mg	NA	FALSE	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1111/head.14128	methodology	1	NA	treatment_name_ipd	rimegepant	rimegepant	NA	FALSE	N02CD06	ATC 5th	rimegepant; oral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists
10.1111/head.14128	methodology	1	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1111/head.14128	methodology	2	NA	treatment_name_ipd	rimegepant	rimegepant	NA	FALSE	N02CD06	ATC 5th	rimegepant; oral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists
10.1111/head.14128	methodology	2	NA	treatment_name_nonipd	galcanezumab	galcanezumab	NA	FALSE	N02CD02	ATC 5th	galcanezumab; parenteral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists
10.1111/head.14128	methodology	3	NA	treatment_name_ipd	rimegepant	rimegepant	NA	FALSE	N02CD06	ATC 5th	rimegepant; oral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists
10.1111/head.14128	methodology	3	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1111/head.14128	methodology	4	NA	treatment_name_ipd	rimegepant	rimegepant	NA	FALSE	N02CD06	ATC 5th	rimegepant; oral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists
10.1111/head.14128	methodology	4	NA	treatment_name_nonipd	erenumab	erenumab	NA	FALSE	N02CD01	ATC 5th	erenumab; parenteral	N	N02	N02C	N02CD	NERVOUS SYSTEM	ANALGESICS	ANTIMIGRAINE PREPARATIONS	Calcitonin gene-related peptide (CGRP) antagonists
10.1111/jdv.15369	methodology	1	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	calcipotriol	NA	FALSE	D05AX02	ATC 5th	calcipotriol; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use
10.1111/jdv.15369	methodology	1	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	betamethasone dipropionate aerosol foam	NA	FALSE	D07XC01	ATC 5th	betamethasone, combinations; topical	D	D07	D07X	D07XC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, OTHER COMBINATIONS	Corticosteroids, potent, other combinations
10.1111/jdv.15369	methodology	1	NA	treatment_name_nonipd	apremilast	apremilast	NA	FALSE	L04AA32	ATC 5th	apremilast; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1111/jdv.15369	methodology	2	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	calcipotriol	NA	FALSE	D05AX02	ATC 5th	calcipotriol; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use
10.1111/jdv.15369	methodology	2	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	betamethasone dipropionate aerosol foam	NA	FALSE	D07XC01	ATC 5th	betamethasone, combinations; topical	D	D07	D07X	D07XC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, OTHER COMBINATIONS	Corticosteroids, potent, other combinations
10.1111/jdv.15369	methodology	2	NA	treatment_name_nonipd	methotrexate	methotrexate	NA	FALSE	L01BA01	ATC 5th	methotrexate; systemic (folic acid analog.)	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.1111/jdv.15369	methodology	3	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	calcipotriol	NA	FALSE	D05AX02	ATC 5th	calcipotriol; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use
10.1111/jdv.15369	methodology	3	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	betamethasone dipropionate aerosol foam	NA	FALSE	D07XC01	ATC 5th	betamethasone, combinations; topical	D	D07	D07X	D07XC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, OTHER COMBINATIONS	Corticosteroids, potent, other combinations
10.1111/jdv.15369	methodology	3	NA	treatment_name_nonipd	acitretin	acitretin	NA	FALSE	D05BB02	ATC 5th	acitretin; oral	D	D05	D05B	D05BB	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR SYSTEMIC USE	Retinoids for treatment of psoriasis
10.1111/jdv.15369	methodology	4	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	calcipotriol	NA	FALSE	D05AX02	ATC 5th	calcipotriol; topical	D	D05	D05A	D05AX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR TOPICAL USE	Other antipsoriatics for topical use
10.1111/jdv.15369	methodology	4	NA	treatment_name_ipd	calcipotriol + betamethasone dipropionate aerosol foam	betamethasone dipropionate aerosol foam	NA	FALSE	D07XC01	ATC 5th	betamethasone, combinations; topical	D	D07	D07X	D07XC	DERMATOLOGICALS	CORTICOSTEROIDS, DERMATOLOGICAL PREPARATIONS	CORTICOSTEROIDS, OTHER COMBINATIONS	Corticosteroids, potent, other combinations
10.1111/jdv.15369	methodology	4	NA	treatment_name_nonipd	fumaric acid esters	fumaric acid esters	NA	FALSE	D05BX51	ATC 5th	fumaric acid derivatives, combinations; systemic	D	D05	D05B	D05BX	DERMATOLOGICALS	ANTIPSORIATICS	ANTIPSORIATICS FOR SYSTEMIC USE	Other antipsoriatics for systemic use
10.1136/rmdopen-2019-001131	methodology	1	NA	treatment_name_ipd	baricitinib	baricitinib	NA	FALSE	L04AA37	ATC 5th	baricitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1136/rmdopen-2019-001131	methodology	1	NA	treatment_name_nonipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.1136/rmdopen-2019-001131	methodology	2	NA	treatment_name_ipd	baricitinib	baricitinib	NA	FALSE	L04AA37	ATC 5th	baricitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1136/rmdopen-2019-001131	methodology	2	NA	treatment_name_nonipd	tocilizumab	tocilizumab	NA	FALSE	L04AC07	ATC 5th	tocilizumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.1136/rmdopen-2019-001131	methodology	3	NA	treatment_name_ipd	baricitinib	baricitinib	NA	FALSE	L04AA37	ATC 5th	baricitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1136/rmdopen-2019-001131	methodology	3	NA	treatment_name_nonipd	tofacitinib	tofacitinib	NA	FALSE	L04AA29	ATC 5th	tofacitinib; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.1155/2017/6121760	methodology	1	NA	treatment_name_ipd	sonidegib	sonidegib	NA	FALSE	L01XJ02	ATC 5th	sonidegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors
10.1155/2017/6121760	methodology	1	NA	treatment_name_nonipd	vismodegib	vismodegib	NA	FALSE	L01XJ01	ATC 5th	vismodegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors
10.1177/1756286420975916	methodology	1	NA	treatment_name_ipd	peginterferon beta-1a	peginterferon beta-1a	NA	FALSE	L03AB13	ATC 5th	peginterferon beta-1a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1177/1756286420975916	methodology	1	NA	treatment_name_nonipd	glatiramer acetate	glatiramer acetate	NA	FALSE	L03AX13	ATC 5th	glatiramer acetate; parenteral	L	L03	L03A	L03AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Other immunostimulants
10.1177/17588359211049639	methodology	1	NA	treatment_name_ipd	olaparib + bevacizumab	olaparib	NA	FALSE	L01XK01	ATC 5th	olaparib; oral	L	L01	L01X	L01XK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Poly (ADP-ribose) polymerase (PARP) inhibitors
10.1177/17588359211049639	methodology	1	NA	treatment_name_ipd	olaparib + bevacizumab	bevacizumab	NA	FALSE	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1177/17588359211049639	methodology	1	NA	treatment_name_nonipd	niraparib	niraparib	NA	FALSE	L01XK02	ATC 5th	niraparib; oral	L	L01	L01X	L01XK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Poly (ADP-ribose) polymerase (PARP) inhibitors
10.1177/17588359211049639	methodology	2	NA	treatment_name_ipd	bevacizumab + placebo	bevacizumab	NA	FALSE	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1177/17588359211049639	methodology	2	NA	treatment_name_ipd	bevacizumab + placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1177/17588359211049639	methodology	2	NA	treatment_name_nonipd	niraparib	niraparib	NA	FALSE	L01XK02	ATC 5th	niraparib; oral	L	L01	L01X	L01XK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Poly (ADP-ribose) polymerase (PARP) inhibitors
10.1177/17588359211049639	methodology	3	NA	treatment_name_ipd	olaparib + bevacizumab	olaparib	NA	FALSE	L01XK01	ATC 5th	olaparib; oral	L	L01	L01X	L01XK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Poly (ADP-ribose) polymerase (PARP) inhibitors
10.1177/17588359211049639	methodology	3	NA	treatment_name_ipd	olaparib + bevacizumab	bevacizumab	NA	FALSE	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1177/17588359211049639	methodology	3	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1177/17588359211049639	methodology	4	NA	treatment_name_ipd	placebo + bevacizumab	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1177/17588359211049639	methodology	4	NA	treatment_name_ipd	placebo + bevacizumab	bevacizumab	NA	FALSE	L01XC07	ATC 5th	bevacizumab; ophthalmic, parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1177/17588359211049639	methodology	4	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1183/13993003.01393-2018	methodology	1	NA	treatment_name_ipd	benralizumab	benralizumab	NA	FALSE	R03DX10	ATC 5th	benralizumab; systemic	R	R03	R03D	R03DX	RESPIRATORY SYSTEM	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	Other systemic drugs for obstructive airway diseases
10.1183/13993003.01393-2018	methodology	1	NA	treatment_name_nonipd	mepolizumab	mepolizumab	NA	FALSE	R03DX09	ATC 5th	mepolizumab; parenteral	R	R03	R03D	R03DX	RESPIRATORY SYSTEM	DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	OTHER SYSTEMIC DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES	Other systemic drugs for obstructive airway diseases
10.1185/03007995.2011.576238	methodology	1	NA	treatment_name_ipd	nilotinib	nilotinib	NA	FALSE	L01EA03	ATC 5th	nilotinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1185/03007995.2011.576238	methodology	1	NA	treatment_name_nonipd	dasatinib	dasatinib	NA	FALSE	L01EA02	ATC 5th	dasatinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1185/03007995.2014.977992	methodology	1	NA	treatment_name_ipd	nilotinib	nilotinib	NA	FALSE	L01EA03	ATC 5th	nilotinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1185/03007995.2014.977992	methodology	1	NA	treatment_name_nonipd	dasatinib	dasatinib	NA	FALSE	L01EA02	ATC 5th	dasatinib; oral	L	L01	L01E	L01EA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Bcr-abl tyrosine kinase inhibitors
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	simeprevir	NA	FALSE	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	1	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	simeprevir	NA	FALSE	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	2	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	simeprevir	NA	FALSE	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	3	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	simeprevir	NA	FALSE	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	4	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	simeprevir	NA	FALSE	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_ipd	simeprevir + peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	peginterferon alfa-2a	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.1185/03007995.2015.1106934	methodology	5	NA	treatment_name_nonipd	peginterferon alfa-2a + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.1186/2162-3619-2-32	methodology	1	NA	treatment_name_ipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1186/2162-3619-2-32	methodology	1	NA	treatment_name_nonipd	sunitinib	sunitinib	NA	FALSE	L01EX01	ATC 5th	L01EX01	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1186/2162-3619-2-32	methodology	2	NA	treatment_name_ipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1186/2162-3619-2-32	methodology	2	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.1186/2162-3619-2-32	methodology	3	NA	treatment_name_ipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1186/2162-3619-2-32	methodology	3	NA	treatment_name_nonipd	sunitinib	sunitinib	NA	FALSE	L01EX01	ATC 5th	L01EX01	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1186/s12885-018-5157-0	methodology	1	NA	treatment_name_ipd	axitinib	axitinib	NA	FALSE	L01EK01	ATC 5th	axitinib; oral	L	L01	L01E	L01EK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
10.1186/s12885-018-5157-0	methodology	1	NA	treatment_name_nonipd	cabozantinib	cabozantinib	NA	FALSE	L01EX07	ATC 5th	L01EX07	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.1186/s12885-018-5157-0	methodology	2	NA	treatment_name_ipd	axitinib	axitinib	NA	FALSE	L01EK01	ATC 5th	axitinib; oral	L	L01	L01E	L01EK	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitors
10.1186/s12885-018-5157-0	methodology	2	NA	treatment_name_nonipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.1186/s13045-021-01144-9	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel	lisocabtagene maraleucel	NA	TRUE	L01XL	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1186/s13045-021-01144-9	methodology	1	NA	treatment_name_nonipd	axicabtagene ciloleucel	axicabtagene ciloleucel	NA	TRUE	L01XX70	ATC 5th	axicabtagene ciloleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1186/s40164-022-00268-z	methodology	1	NA	treatment_name_ipd	lisocabtagene maraleucel	lisocabtagene maraleucel	NA	TRUE	L01XL	NA	NA	L	L01	L01X	L01XL	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	ANTINEOPLASTIC CELL AND GENE THERAPY
10.1186/s40164-022-00268-z	methodology	1	NA	treatment_name_nonipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.1186/s40734-017-0051-5	methodology	1	NA	treatment_name_ipd	deutetrabenazine	deutetrabenazine	NA	FALSE	N07XX16	ATC 5th	deutetrabenazine; oral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs
10.1186/s40734-017-0051-5	methodology	1	NA	treatment_name_nonipd	tetrabenazine	tetrabenazine	NA	FALSE	N07XX06	ATC 5th	tetrabenazine; oral	N	N07	N07X	N07XX	NERVOUS SYSTEM	OTHER NERVOUS SYSTEM DRUGS	OTHER NERVOUS SYSTEM DRUGS	Other nervous system drugs
10.1210/clinem/dgab905	methodology	1	NA	treatment_name_ipd	semaglutide 2.0 mg	semaglutide 2.0 mg	NA	FALSE	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1210/clinem/dgab905	methodology	1	NA	treatment_name_nonipd	dulaglutide 3.0 mg	dulaglutide 3.0 mg	NA	FALSE	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1210/clinem/dgab905	methodology	2	NA	treatment_name_ipd	semaglutide 2.0 mg	semaglutide 2.0 mg	NA	FALSE	A10BJ06	ATC 5th	semaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1210/clinem/dgab905	methodology	2	NA	treatment_name_nonipd	dulaglutide 4.5 mg	dulaglutide 4.5 mg	NA	FALSE	A10BJ05	ATC 5th	dulaglutide; parenteral	A	A10	A10B	A10BJ	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Glucagon-like peptide-1 (GLP-1) analogues
10.1634/theoncologist.2017-0103	methodology	1	NA	treatment_name_ipd	daratumumab	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1634/theoncologist.2017-0103	methodology	1	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone	pomalidomide	NA	FALSE	L04AX06	ATC 5th	pomalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1634/theoncologist.2017-0103	methodology	1	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone	low-dose dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.1634/theoncologist.2017-0103	methodology	2	NA	treatment_name_ipd	daratumumab	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.1634/theoncologist.2017-0103	methodology	2	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone	pomalidomide	NA	FALSE	L04AX06	ATC 5th	pomalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.1634/theoncologist.2017-0103	methodology	2	NA	treatment_name_nonipd	pomalidomide + low-dose dexamethasone	low-dose dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2147/ceor.s203482	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	glasdegib	NA	FALSE	L01XJ03	ATC 5th	glasdegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors
10.2147/ceor.s203482	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	low-dose cytarabine	NA	FALSE	L01BC01	ATC 5th	cytarabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.2147/ceor.s203482	methodology	1	NA	treatment_name_nonipd	azacitidine	azacitidine	NA	FALSE	L01BC07	ATC 5th	azacitidine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.2147/ceor.s203482	methodology	2	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	glasdegib	NA	FALSE	L01XJ03	ATC 5th	glasdegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors
10.2147/ceor.s203482	methodology	2	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	low-dose cytarabine	NA	FALSE	L01BC01	ATC 5th	cytarabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.2147/ceor.s203482	methodology	2	NA	treatment_name_nonipd	decitabine	decitabine	NA	FALSE	L01BC08	ATC 5th	decitabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.2147/cmar.s163478	methodology	1	NA	treatment_name_ipd	ribociclib	ribociclib	NA	FALSE	L01EF02	ATC 5th	ribociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2147/cmar.s163478	methodology	1	NA	treatment_name_nonipd	palbociclib	palbociclib	NA	FALSE	L01EF01	ATC 5th	palbociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2147/cmar.s325043	methodology	1	NA	treatment_name_ipd	ribociclib + fulvestrant	ribociclib	NA	FALSE	L01EF02	ATC 5th	ribociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2147/cmar.s325043	methodology	1	NA	treatment_name_ipd	ribociclib + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2147/cmar.s325043	methodology	1	NA	treatment_name_nonipd	palbociclib + letrozole	palbociclib	NA	FALSE	L01EF01	ATC 5th	palbociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2147/cmar.s325043	methodology	1	NA	treatment_name_nonipd	palbociclib + letrozole	letrozole	NA	FALSE	L02BG04	ATC 5th	letrozole; oral	L	L02	L02B	L02BG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Aromatase inhibitors
10.2147/cmar.s325043	methodology	2	NA	treatment_name_ipd	placebo + fulvestrant	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.2147/cmar.s325043	methodology	2	NA	treatment_name_ipd	placebo + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2147/cmar.s325043	methodology	2	NA	treatment_name_nonipd	letrozole	letrozole	NA	FALSE	L02BG04	ATC 5th	letrozole; oral	L	L02	L02B	L02BG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Aromatase inhibitors
10.2147/jbm.s104074	methodology	1	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)	bay 81-8973 (recombinant factor viii)	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s104074	methodology	1	NA	treatment_name_nonipd	rahf-pfm	rahf-pfm	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s104074	methodology	2	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)	bay 81-8973 (recombinant factor viii)	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s104074	methodology	2	NA	treatment_name_nonipd	rahf-pfm	rahf-pfm	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s104074	methodology	3	NA	treatment_name_ipd	bay 81-8973 (recombinant factor viii)	bay 81-8973 (recombinant factor viii)	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s104074	methodology	3	NA	treatment_name_nonipd	turoctocog alfa	turoctocog alfa	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	1	NA	treatment_name_ipd	bay 94-9027	bay 94-9027	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	1	NA	treatment_name_nonipd	rfviiifc	rfviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	2	NA	treatment_name_ipd	bay 94-9027	bay 94-9027	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	2	NA	treatment_name_nonipd	bax 855	bax 855	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	3	NA	treatment_name_ipd	bay 94-9027	bay 94-9027	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	3	NA	treatment_name_nonipd	rahf-pfm 2004	rahf-pfm 2004	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	4	NA	treatment_name_ipd	bay 94-9027	bay 94-9027	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s206806	methodology	4	NA	treatment_name_nonipd	rahf-pfm 2012	rahf-pfm 2012	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s288283	methodology	1	NA	treatment_name_ipd	rfviiifc	rfviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s288283	methodology	1	NA	treatment_name_nonipd	emicizumab every week	emicizumab every week	NA	FALSE	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics
10.2147/jbm.s288283	methodology	2	NA	treatment_name_ipd	rfviiifc	rfviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s288283	methodology	2	NA	treatment_name_nonipd	emicizumab every 2 weeks	emicizumab every 2 weeks	NA	FALSE	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics
10.2147/jbm.s288283	methodology	3	NA	treatment_name_ipd	rfviiifc	rfviiifc	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s288283	methodology	3	NA	treatment_name_nonipd	emicizumab every 4 weeks	emicizumab every 4 weeks	NA	FALSE	B02BX06	ATC 5th	emicizumab; parenteral	B	B02	B02B	B02BX	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Other systemic hemostatics
10.2147/jbm.s312885	methodology	1	NA	treatment_name_ipd	prior prophylaxis rfixfc	prior prophylaxis rfixfc	NA	FALSE	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s312885	methodology	1	NA	treatment_name_nonipd	prior prophylaxis rix-fp	prior prophylaxis rix-fp	NA	FALSE	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s312885	methodology	2	NA	treatment_name_ipd	prior episodic treatment rfixfc	prior episodic treatment rfixfc	NA	FALSE	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s312885	methodology	2	NA	treatment_name_nonipd	prior episodic treatment rix-fp	prior episodic treatment rix-fp	NA	FALSE	B02BD04	ATC 5th	coagulation factor IX; parenteral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s321288	methodology	1	NA	treatment_name_ipd	damoctocog alfa pegol (bay 94-9027)	damoctocog alfa pegol (bay 94-9027)	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/jbm.s321288	methodology	1	NA	treatment_name_nonipd	turoctocog alfa pegol (n8-gp)	turoctocog alfa pegol (n8-gp)	NA	FALSE	B02BD02	ATC 5th	coagulation factor VIII; parenteral, topical, urethral	B	B02	B02B	B02BD	BLOOD AND BLOOD FORMING ORGANS	ANTIHEMORRHAGICS	VITAMIN K AND OTHER HEMOSTATICS	Blood coagulation factors
10.2147/ptt.s326121	methodology	1	NA	treatment_name_ipd	brodalumab	brodalumab	NA	FALSE	L04AC12	ATC 5th	brodalumab; systemic	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.2147/ptt.s326121	methodology	1	NA	treatment_name_nonipd	guselkumab	guselkumab	NA	FALSE	L04AC16	ATC 5th	guselkumab; systemic	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.2165/11592490-000000000-00000	methodology	1	NA	treatment_name_ipd	vildagliptin 50 mg twice daily	vildagliptin 50 mg twice daily	NA	FALSE	A10BH02	ATC 5th	vildagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors
10.2165/11592490-000000000-00000	methodology	1	NA	treatment_name_nonipd	sitagliptin 50 mg once daily	sitagliptin 50 mg once daily	NA	FALSE	A10BH01	ATC 5th	sitagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors
10.2165/11592490-000000000-00000	methodology	2	NA	treatment_name_ipd	vildagliptin 50 mg twice daily	vildagliptin 50 mg twice daily	NA	FALSE	A10BH02	ATC 5th	vildagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors
10.2165/11592490-000000000-00000	methodology	2	NA	treatment_name_nonipd	sitagliptin 50 mg once daily	sitagliptin 50 mg once daily	NA	FALSE	A10BH01	ATC 5th	sitagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors
10.2165/11592490-000000000-00000	methodology	3	NA	treatment_name_ipd	vildagliptin 50 mg twice daily	vildagliptin 50 mg twice daily	NA	FALSE	A10BH02	ATC 5th	vildagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors
10.2165/11592490-000000000-00000	methodology	3	NA	treatment_name_nonipd	sitagliptin 100 mg once daily	sitagliptin 100 mg once daily	NA	FALSE	A10BH01	ATC 5th	sitagliptin; oral	A	A10	A10B	A10BH	ALIMENTARY TRACT AND METABOLISM	DRUGS USED IN DIABETES	BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS	Dipeptidyl peptidase 4 (DPP-4) inhibitors
10.2217/cer-2016-0085	methodology	1	NA	treatment_name_ipd	delayed-release dimethyl fumarate	delayed-release dimethyl fumarate	NA	FALSE	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/cer-2016-0085	methodology	1	NA	treatment_name_nonipd	glatiramer acetate	glatiramer acetate	NA	FALSE	L03AX13	ATC 5th	glatiramer acetate; parenteral	L	L03	L03A	L03AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Other immunostimulants
10.2217/cer-2016-0085	methodology	2	NA	treatment_name_ipd	delayed-release dimethyl fumarate	delayed-release dimethyl fumarate	NA	FALSE	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/cer-2016-0085	methodology	2	NA	treatment_name_nonipd	glatiramer acetate	glatiramer acetate	NA	FALSE	L03AX13	ATC 5th	glatiramer acetate; parenteral	L	L03	L03A	L03AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Other immunostimulants
10.2217/cer-2016-0085	methodology	3	NA	treatment_name_ipd	delayed-release dimethyl fumarate	delayed-release dimethyl fumarate	NA	FALSE	L04AX07	ATC 5th	dimethyl fumarate; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/cer-2016-0085	methodology	3	NA	treatment_name_nonipd	glatiramer acetate	glatiramer acetate	NA	FALSE	L03AX13	ATC 5th	glatiramer acetate; parenteral	L	L03	L03A	L03AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Other immunostimulants
10.2217/cer-2018-0020	methodology	1	NA	treatment_name_ipd	sunitinib	sunitinib	NA	FALSE	L01EX01	ATC 5th	L01EX01	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/cer-2018-0020	methodology	1	NA	treatment_name_nonipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.2217/cer-2018-0020	methodology	2	NA	treatment_name_ipd	sunitinib	sunitinib	NA	FALSE	L01EX01	ATC 5th	L01EX01	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/cer-2018-0020	methodology	2	NA	treatment_name_nonipd	everolimus	everolimus	NA	FALSE	L01EG02	ATC 5th	everolimus; oral (mammalian target of rapamycin kinase inhibitors (mtor))	L	L01	L01E	L01EG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mammalian target of rapamycin (mTOR) kinase inhibitors
10.2217/cer-2018-0141	methodology	1	NA	treatment_name_ipd	secukinumab 150mg	secukinumab 150mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.2217/cer-2018-0141	methodology	1	NA	treatment_name_nonipd	infliximab	infliximab	NA	FALSE	L04AB02	ATC 5th	infliximab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.2217/cer-2018-0141	methodology	2	NA	treatment_name_ipd	secukinumab 300mg	secukinumab 300mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.2217/cer-2018-0141	methodology	2	NA	treatment_name_nonipd	infliximab	infliximab	NA	FALSE	L04AB02	ATC 5th	infliximab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.2217/cer-2019-0145	methodology	1	NA	treatment_name_ipd	nivolumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/cer-2019-0145	methodology	1	NA	treatment_name_nonipd	routine clinical practice	routine clinical practice	supportive or standard of care	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.2217/cer-2019-0169	methodology	1	NA	treatment_name_ipd	ozanimod	ozanimod	NA	FALSE	L04AA38	ATC 5th	ozanimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.2217/cer-2019-0169	methodology	1	NA	treatment_name_nonipd	fingolimod	fingolimod	NA	FALSE	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.2217/cer-2019-0169	methodology	2	NA	treatment_name_ipd	ozanimod	ozanimod	NA	FALSE	L04AA38	ATC 5th	ozanimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.2217/cer-2019-0169	methodology	2	NA	treatment_name_nonipd	fingolimod	fingolimod	NA	FALSE	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.2217/cer-2019-0169	methodology	3	NA	treatment_name_ipd	ozanimod	ozanimod	NA	FALSE	L04AA38	ATC 5th	ozanimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.2217/cer-2019-0169	methodology	3	NA	treatment_name_nonipd	fingolimod	fingolimod	NA	FALSE	L04AA27	ATC 5th	fingolimod; oral	L	L04	L04A	L04AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Selective immunosuppressants
10.2217/cer-2020-0063	methodology	1	NA	treatment_name_ipd	entrectinib	entrectinib	NA	FALSE	L01EX14	ATC 5th	L01EX14	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/cer-2020-0063	methodology	1	NA	treatment_name_nonipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_ipd	entrectinib	entrectinib	NA	FALSE	L01EX14	ATC 5th	L01EX14	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_nonipd	pemetrexed + platinum followed by pemetrexed maintenance	pemetrexed	NA	FALSE	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_nonipd	pemetrexed + platinum followed by pemetrexed maintenance	platinum	NA	FALSE	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds
10.2217/cer-2020-0063	methodology	2	NA	treatment_name_nonipd	pemetrexed + platinum followed by pemetrexed maintenance	pemetrexed maintenance	NA	FALSE	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.2217/cer-2020-0063	methodology	3	NA	treatment_name_ipd	entrectinib	entrectinib	NA	FALSE	L01EX14	ATC 5th	L01EX14	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/cer-2020-0063	methodology	3	NA	treatment_name_nonipd	pemetrexed/docetaxel	pemetrexed	NA	FALSE	L01BA04	ATC 5th	pemetrexed; inhalant, parenteral	L	L01	L01B	L01BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Folic acid analogues
10.2217/cer-2020-0063	methodology	3	NA	treatment_name_nonipd	pemetrexed/docetaxel	docetaxel	NA	FALSE	L01CD02	ATC 5th	docetaxel; parenteral	L	L01	L01C	L01CD	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Taxanes
10.2217/cer-2020-0069	methodology	1	NA	treatment_name_ipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.2217/cer-2020-0069	methodology	1	NA	treatment_name_nonipd	blinatumomab	blinatumomab	NA	FALSE	L01XC19	ATC 5th	blinatumomab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/cer-2020-0069	methodology	2	NA	treatment_name_ipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.2217/cer-2020-0069	methodology	2	NA	treatment_name_nonipd	clofarabine	clofarabine	NA	FALSE	L01BB06	ATC 5th	clofarabine; parenteral	L	L01	L01B	L01BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Purine analogues
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_ipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_nonipd	clofarabine + etoposide plus cyclophosphamide	clofarabine	NA	FALSE	L01BB06	ATC 5th	clofarabine; parenteral	L	L01	L01B	L01BB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Purine analogues
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_nonipd	clofarabine + etoposide plus cyclophosphamide	etoposide plus cyclophosphamide	NA	FALSE	L01CB01	ATC 5th	etoposide; systemic	L	L01	L01C	L01CB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Podophyllotoxin derivatives
10.2217/cer-2020-0069	methodology	3	NA	treatment_name_nonipd	clofarabine + etoposide plus cyclophosphamide	etoposide plus cyclophosphamide	NA	FALSE	L01AA01	ATC 5th	cyclophosphamide; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.2217/cer-2020-0069	methodology	4	NA	treatment_name_ipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.2217/cer-2020-0069	methodology	4	NA	treatment_name_nonipd	polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)	polychemotherapy	NA	FALSE	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds
10.2217/cer-2020-0069	methodology	4	NA	treatment_name_nonipd	polychemotherapy/high-dose single-agent regimens/stem-cell transplantation (salvage-1)	stem-cell transplantation (salvage-1)	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.2217/cer-2020-0069	methodology	5	NA	treatment_name_ipd	tisagenlecleucel	tisagenlecleucel	NA	FALSE	L01XX71	ATC 5th	tisagenlecleucel; parenteral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.2217/cer-2020-0069	methodology	5	NA	treatment_name_nonipd	palliative therapy/salvage therapy  second stem-cell transplantation (salvage-2)	palliative therapy	procedure	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.2217/cer-2020-0236	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/cer-2020-0236	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/cer-2020-0236	methodology	1	NA	treatment_name_nonipd	placebo	placebo	placebo	FALSE	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA	NA
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant	palbociclib	NA	FALSE	L01EF01	ATC 5th	palbociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant	abemaciclib	NA	FALSE	L01EF03	ATC 5th	abemaciclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2217/cer-2020-0272	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_ipd	palbociclib + fulvestrant	palbociclib	NA	FALSE	L01EF01	ATC 5th	palbociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_ipd	palbociclib + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_nonipd	ribociclib + fulvestrant	ribociclib	NA	FALSE	L01EF02	ATC 5th	ribociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2217/cer-2020-0272	methodology	2	NA	treatment_name_nonipd	ribociclib + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	glasdegib	NA	FALSE	L01XJ03	ATC 5th	glasdegib; oral	L	L01	L01X	L01XJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Hedgehog pathway inhibitors
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_ipd	glasdegib + low-dose cytarabine	low-dose cytarabine	NA	FALSE	L01BC01	ATC 5th	cytarabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_nonipd	venetoclax + low-dose cytarabine	venetoclax	NA	FALSE	L01XX52	ATC 5th	venetoclax; oral	L	L01	L01X	L01XX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Other antineoplastic agents
10.2217/cer-2020-0280	methodology	1	NA	treatment_name_nonipd	venetoclax + low-dose cytarabine	low-dose cytarabine	NA	FALSE	L01BC01	ATC 5th	cytarabine; systemic	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.2217/cer-2021-0178	methodology	1	NA	treatment_name_ipd	apomorphine sublingual film	apomorphine sublingual film	NA	FALSE	G04BE07	ATC 5th	apomorphine; sublingual	G	G04	G04B	G04BE	GENITO URINARY SYSTEM AND SEX HORMONES	UROLOGICALS	UROLOGICALS	Drugs used in erectile dysfunction
10.2217/cer-2021-0178	methodology	1	NA	treatment_name_nonipd	levodopa inhalation powder	levodopa inhalation powder	NA	FALSE	N04BA01	ATC 5th	levodopa; oral	N	N04	N04B	N04BA	NERVOUS SYSTEM	ANTI-PARKINSON DRUGS	DOPAMINERGIC AGENTS	Dopa and dopa derivatives
10.2217/cer-2021-0216	methodology	1	NA	treatment_name_ipd	risdiplam	risdiplam	NA	FALSE	M09AX10	ATC 5th	risdiplam; oral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.2217/cer-2021-0216	methodology	1	NA	treatment_name_nonipd	nusinersen	nusinersen	NA	FALSE	M09AX07	ATC 5th	nusinersen; systemic	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.2217/cer-2021-0216	methodology	2	NA	treatment_name_ipd	risdiplam	risdiplam	NA	FALSE	M09AX10	ATC 5th	risdiplam; oral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.2217/cer-2021-0216	methodology	2	NA	treatment_name_nonipd	onasemnogene abeparvovec	onasemnogene abeparvovec	NA	FALSE	M09AX09	ATC 5th	onasemnogene abeparvovec; parenteral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.2217/cer-2021-0216	methodology	3	NA	treatment_name_ipd	risdiplam	risdiplam	NA	FALSE	M09AX10	ATC 5th	risdiplam; oral	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.2217/cer-2021-0216	methodology	3	NA	treatment_name_nonipd	nusinersen	nusinersen	NA	FALSE	M09AX07	ATC 5th	nusinersen; systemic	M	M09	M09A	M09AX	MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	OTHER DRUGS FOR DISORDERS OF THE MUSCULO-SKELETAL SYSTEM	Other drugs for disorders of the musculo-skeletal system
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant	palbociclib	NA	FALSE	L01EF01	ATC 5th	palbociclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_ipd	palbociclib + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant	abemaciclib	NA	FALSE	L01EF03	ATC 5th	abemaciclib; oral	L	L01	L01E	L01EF	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Cyclin-dependent kinase (CDK) inhibitors
10.2217/cer-2021-0221	methodology	1	NA	treatment_name_nonipd	abemaciclib + fulvestrant	fulvestrant	NA	FALSE	L02BA03	ATC 5th	fulvestrant; parenteral	L	L02	L02B	L02BA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ENDOCRINE THERAPY	HORMONE ANTAGONISTS AND RELATED AGENTS	Anti-estrogens
10.2217/cer.15.33	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	1	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin	telaprevir	NA	FALSE	J05AP02	ATC 5th	telaprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	1	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	1	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	2	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	2	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	2	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin	boceprevir	NA	FALSE	J05AP03	ATC 5th	boceprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	2	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	2	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	3	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	3	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	3	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin	simeprevir	NA	FALSE	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	3	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	3	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	4	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	4	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	4	NA	treatment_name_nonipd	sofosbuvir + peginterferon- + ribavirin	sofosbuvir	NA	FALSE	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	4	NA	treatment_name_nonipd	sofosbuvir + peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	4	NA	treatment_name_nonipd	sofosbuvir + peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	5	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	5	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	5	NA	treatment_name_nonipd	peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	5	NA	treatment_name_nonipd	peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	6	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	6	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	6	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin	telaprevir	NA	FALSE	J05AP02	ATC 5th	telaprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	6	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	6	NA	treatment_name_nonipd	telaprevir + peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	7	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	7	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	7	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin	boceprevir	NA	FALSE	J05AP03	ATC 5th	boceprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	7	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	7	NA	treatment_name_nonipd	boceprevir + peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	8	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	8	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	8	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin	simeprevir	NA	FALSE	J05AP05	ATC 5th	simeprevir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	8	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	8	NA	treatment_name_nonipd	simeprevir + peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	9	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	9	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.33	methodology	9	NA	treatment_name_nonipd	peginterferon- + ribavirin	peginterferon-	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.33	methodology	9	NA	treatment_name_nonipd	peginterferon- + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.49	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.49	methodology	1	NA	treatment_name_ipd	daclatasvir + sofosbuvir	sofosbuvir	NA	FALSE	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.49	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin	sofosbuvir	NA	FALSE	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.49	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.49	methodology	2	NA	treatment_name_ipd	daclatasvir + sofosbuvir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.49	methodology	2	NA	treatment_name_ipd	daclatasvir + sofosbuvir	sofosbuvir	NA	FALSE	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.49	methodology	2	NA	treatment_name_nonipd	peginterferon-alfa + ribavirin	peginterferon-alfa	NA	FALSE	L03AB11	ATC 5th	peginterferon alfa-2a; parenteral	L	L03	L03A	L03AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSTIMULANTS	IMMUNOSTIMULANTS	Interferons
10.2217/cer.15.49	methodology	2	NA	treatment_name_nonipd	peginterferon-alfa + ribavirin	ribavirin	NA	FALSE	J05AP01	ATC 5th	ribavirin; inhalant, oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.69	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir	daclatasvir	NA	FALSE	J05AP07	ATC 5th	daclatasvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.69	methodology	1	NA	treatment_name_ipd	daclatasvir + asunaprevir	asunaprevir	NA	FALSE	J05AP06	ATC 5th	asunaprevir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.69	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ledipasvir	sofosbuvir	NA	FALSE	J05AP08	ATC 5th	sofosbuvir; oral	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/cer.15.69	methodology	1	NA	treatment_name_nonipd	sofosbuvir + ledipasvir	ledipasvir	NA	FALSE	J05AP51	ATC 5th	sofosbuvir and ledipasvir; systemic	J	J05	J05A	J05AP	ANTIINFECTIVES FOR SYSTEMIC USE	ANTIVIRALS FOR SYSTEMIC USE	DIRECT ACTING ANTIVIRALS	Antivirals for treatment of HCV infections
10.2217/fon-2020-0823	methodology	1	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	1	NA	treatment_name_nonipd	erlotinib	erlotinib	NA	FALSE	L01EB02	ATC 5th	erlotinib; oral (epidermal growth factor receptor (egfr) tyrosine kinase inhibitors)	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
10.2217/fon-2020-0823	methodology	10	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	10	NA	treatment_name_nonipd	gefitinib	gefitinib	NA	FALSE	L01EB01	ATC 5th	gefitinib; oral (epidermal growth factor receptor (egfr) tyrosine kinase inhibitors)	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
10.2217/fon-2020-0823	methodology	11	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	11	NA	treatment_name_nonipd	dacomitinib	dacomitinib	NA	FALSE	L01EB07	ATC 5th	dacomitinib; oral	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
10.2217/fon-2020-0823	methodology	12	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	12	NA	treatment_name_nonipd	dacomitinib	dacomitinib	NA	FALSE	L01EB07	ATC 5th	dacomitinib; oral	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
10.2217/fon-2020-0823	methodology	13	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	13	NA	treatment_name_nonipd	panitumumab	panitumumab	NA	FALSE	L01XC08	ATC 5th	panitumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	14	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	14	NA	treatment_name_nonipd	panitumumab	panitumumab	NA	FALSE	L01XC08	ATC 5th	panitumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	15	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	15	NA	treatment_name_nonipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	16	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	16	NA	treatment_name_nonipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	17	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	17	NA	treatment_name_nonipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	18	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	18	NA	treatment_name_nonipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	19	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	19	NA	treatment_name_nonipd	cetuximab	cetuximab	NA	FALSE	L01XC06	ATC 5th	cetuximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	2	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	2	NA	treatment_name_nonipd	erlotinib	erlotinib	NA	FALSE	L01EB02	ATC 5th	erlotinib; oral (epidermal growth factor receptor (egfr) tyrosine kinase inhibitors)	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
10.2217/fon-2020-0823	methodology	20	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	20	NA	treatment_name_nonipd	cetuximab	cetuximab	NA	FALSE	L01XC06	ATC 5th	cetuximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	3	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	3	NA	treatment_name_nonipd	platinum-based chemotherapy	platinum-based chemotherapy	NA	FALSE	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds
10.2217/fon-2020-0823	methodology	4	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	4	NA	treatment_name_nonipd	platinum-based chemotherapy	platinum-based chemotherapy	NA	FALSE	L01XA	ATC 4th	Platinum compounds	L	L01	L01X	L01XA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Platinum compounds
10.2217/fon-2020-0823	methodology	5	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	5	NA	treatment_name_nonipd	cetuximab	cetuximab	NA	FALSE	L01XC06	ATC 5th	cetuximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	6	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	6	NA	treatment_name_nonipd	cetuximab	cetuximab	NA	FALSE	L01XC06	ATC 5th	cetuximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	7	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	7	NA	treatment_name_nonipd	cetuximab	cetuximab	NA	FALSE	L01XC06	ATC 5th	cetuximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	8	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	8	NA	treatment_name_nonipd	cetuximab	cetuximab	NA	FALSE	L01XC06	ATC 5th	cetuximab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	9	NA	treatment_name_ipd	cemiplimab	cemiplimab	NA	FALSE	L01XC33	ATC 5th	cemiplimab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/fon-2020-0823	methodology	9	NA	treatment_name_nonipd	gefitinib	gefitinib	NA	FALSE	L01EB01	ATC 5th	gefitinib; oral (epidermal growth factor receptor (egfr) tyrosine kinase inhibitors)	L	L01	L01E	L01EB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors
10.2217/fon-2021-1102	methodology	1	NA	treatment_name_ipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.2217/fon-2021-1102	methodology	1	NA	treatment_name_nonipd	entrectinib	entrectinib	NA	FALSE	L01EX14	ATC 5th	L01EX14	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/fon-2021-1102	methodology	2	NA	treatment_name_ipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.2217/fon-2021-1102	methodology	2	NA	treatment_name_nonipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.2217/fon-2021-1102	methodology	3	NA	treatment_name_ipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.2217/fon-2021-1102	methodology	3	NA	treatment_name_nonipd	crizotinib	crizotinib	NA	FALSE	L01ED01	ATC 5th	crizotinib; oral	L	L01	L01E	L01ED	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Anaplastic lymphoma kinase (ALK) inhibitors
10.2217/fon-2021-1509	methodology	1	NA	treatment_name_ipd	avapritinib	avapritinib	NA	FALSE	L01EX18	ATC 5th	L01EX18	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/fon-2021-1509	methodology	1	NA	treatment_name_nonipd	midostaurin	midostaurin	NA	FALSE	L01EX10	ATC 5th	L01EX10	L	L01	L01E	L01EX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Other protein kinase inhibitors
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_ipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib	dabrafenib	NA	FALSE	L01EC02	ATC 5th	dabrafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors
10.2217/imt-2018-0208	methodology	1	NA	treatment_name_nonipd	dabrafenib + trametinib	trametinib	NA	FALSE	L01EE01	ATC 5th	trametinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_ipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_nonipd	vemurafenib + cobimetinib	vemurafenib	NA	FALSE	L01EC01	ATC 5th	vemurafenib; oral	L	L01	L01E	L01EC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	B-raf serine-threonine kinase (BRAF) inhibitors
10.2217/imt-2018-0208	methodology	2	NA	treatment_name_nonipd	vemurafenib + cobimetinib	cobimetinib	NA	FALSE	L01EE02	ATC 5th	cobimetinib; oral	L	L01	L01E	L01EE	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Mitogen-activated protein kinase (MEK) inhibitors
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	thalidomide	NA	FALSE	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	lenalidomide	NA	FALSE	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	1	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	thalidomide	NA	FALSE	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	lenalidomide	NA	FALSE	L04AX04	ATC 5th	lenalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	2	NA	treatment_name_nonipd	bortezomib + lenalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	thalidomide	NA	FALSE	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	cyclophosphamide	NA	FALSE	L01AA01	ATC 5th	cyclophosphamide; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.2217/imt-2020-0266	methodology	3	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	thalidomide	NA	FALSE	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	cyclophosphamide	NA	FALSE	L01AA01	ATC 5th	cyclophosphamide; systemic	L	L01	L01A	L01AA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ALKYLATING AGENTS	Nitrogen mustard analogues
10.2217/imt-2020-0266	methodology	4	NA	treatment_name_nonipd	bortezomib + cyclophosphamide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	daratumumab	NA	FALSE	L01XC24	ATC 5th	daratumumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	thalidomide	NA	FALSE	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_ipd	daratumumab + bortezomib + thalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_nonipd	bortezomib + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	5	NA	treatment_name_nonipd	bortezomib + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	thalidomide	NA	FALSE	L04AX02	ATC 5th	thalidomide; oral	L	L04	L04A	L04AX	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Other immunosuppressants
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_ipd	bortezomib + thalidomide + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_nonipd	bortezomib + dexamethasone	bortezomib	NA	FALSE	L01XG01	ATC 5th	bortezomib; parenteral	L	L01	L01X	L01XG	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Proteasome inhibitors
10.2217/imt-2020-0266	methodology	6	NA	treatment_name_nonipd	bortezomib + dexamethasone	dexamethasone	NA	FALSE	H02AB02	ATC 5th	dexamethasone; systemic	H	H02	H02A	H02AB	SYSTEMIC HORMONAL PREPARATIONS, EXCL. SEX HORMONES AND INSULINS	CORTICOSTEROIDS FOR SYSTEMIC USE	CORTICOSTEROIDS FOR SYSTEMIC USE, PLAIN	Glucocorticoids
10.2217/imt-2021-0273	methodology	1	NA	treatment_name_ipd	pembrolizumab	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2021-0273	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.2217/imt-2021-0273	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.3111/13696998.2013.768530	methodology	1	NA	treatment_name_ipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.3111/13696998.2013.768530	methodology	1	NA	treatment_name_nonipd	etanercept	etanercept	NA	FALSE	L04AB01	ATC 5th	etanercept; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.3111/13696998.2013.768530	methodology	2	NA	treatment_name_ipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.3111/13696998.2013.768530	methodology	2	NA	treatment_name_nonipd	infliximab	infliximab	NA	FALSE	L04AB02	ATC 5th	infliximab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.3390/biom11060780	methodology	1	NA	treatment_name_ipd	gemcitabine + nab-paclitaxel	gemcitabine	NA	FALSE	L01BC05	ATC 5th	gemcitabine; parenteral	L	L01	L01B	L01BC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	ANTIMETABOLITES	Pyrimidine analogues
10.3390/biom11060780	methodology	1	NA	treatment_name_ipd	gemcitabine + nab-paclitaxel	nab-paclitaxel	NA	FALSE	L01CD01	ATC 5th	paclitaxel; systemic	L	L01	L01C	L01CD	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PLANT ALKALOIDS AND OTHER NATURAL PRODUCTS	Taxanes
10.3390/biom11060780	methodology	1	NA	treatment_name_nonipd	folfirinox	folfirinox	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.3390/cancers12123648	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy	pembrolizumab	NA	FALSE	L01XC18	ATC 5th	pembrolizumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.3390/cancers12123648	methodology	1	NA	treatment_name_ipd	pembrolizumab + chemotherapy	chemotherapy	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.3390/cancers12123648	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab	nivolumab	NA	FALSE	L01XC17	ATC 5th	nivolumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.3390/cancers12123648	methodology	1	NA	treatment_name_nonipd	nivolumab + ipilimumab	ipilimumab	NA	FALSE	L01XC11	ATC 5th	ipilimumab; parenteral	L	L01	L01X	L01XC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	OTHER ANTINEOPLASTIC AGENTS	Monoclonal antibodies
10.3390/cancers13102406	methodology	1	NA	treatment_name_ipd	padua surgical aggressive downstaging	padua surgical aggressive downstaging	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.3390/cancers13102406	methodology	1	NA	treatment_name_nonipd	xxl protocol downstaging	xxl protocol downstaging	NA	FALSE	L01	ATC 2nd	ANTINEOPLASTIC AGENTS	L	L01	NA	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	NA	NA
10.36469/jheor.2021.19008	methodology	1	NA	treatment_name_ipd	remestemcel-l-rknd	remestemcel-l-rknd	NA	FALSE	L04A	ATC 3rd	IMMUNOSUPPRESSANTS	L	L04	L04A	NA	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	NA
10.36469/jheor.2021.19008	methodology	1	NA	treatment_name_nonipd	ruxolitinib	ruxolitinib	NA	FALSE	L01EJ01	ATC 5th	ruxolitinib; oral	L	L01	L01E	L01EJ	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	ANTINEOPLASTIC AGENTS	PROTEIN KINASE INHIBITORS	Janus-associated kinase (JAK) inhibitors
10.5152/eurjrheum.2018.18162	methodology	1	NA	treatment_name_ipd	secukinumab	secukinumab	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.5152/eurjrheum.2018.18162	methodology	1	NA	treatment_name_nonipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.5152/eurjrheum.2018.18162	methodology	2	NA	treatment_name_ipd	secukinumab	secukinumab	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.5152/eurjrheum.2018.18162	methodology	2	NA	treatment_name_nonipd	adalimumab	adalimumab	NA	FALSE	L04AB04	ATC 5th	adalimumab; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.5152/eurjrheum.2019.19057	methodology	1	NA	treatment_name_ipd	secukinumab 150 mg	secukinumab 150 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.5152/eurjrheum.2019.19057	methodology	1	NA	treatment_name_nonipd	etanercept	etanercept	NA	FALSE	L04AB01	ATC 5th	etanercept; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.5152/eurjrheum.2019.19057	methodology	2	NA	treatment_name_ipd	secukinumab 150 mg	secukinumab 150 mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.5152/eurjrheum.2019.19057	methodology	2	NA	treatment_name_nonipd	etanercept	etanercept	NA	FALSE	L04AB01	ATC 5th	etanercept; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.5152/eurjrheum.2019.19057	methodology	3	NA	treatment_name_ipd	secukinumab 300mg	secukinumab 300mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.5152/eurjrheum.2019.19057	methodology	3	NA	treatment_name_nonipd	etanercept	etanercept	NA	FALSE	L04AB01	ATC 5th	etanercept; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
10.5152/eurjrheum.2019.19057	methodology	4	NA	treatment_name_ipd	secukinumab 300mg	secukinumab 300mg	NA	FALSE	L04AC10	ATC 5th	secukinumab; parenteral	L	L04	L04A	L04AC	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Interleukin inhibitors
10.5152/eurjrheum.2019.19057	methodology	4	NA	treatment_name_nonipd	etanercept	etanercept	NA	FALSE	L04AB01	ATC 5th	etanercept; parenteral	L	L04	L04A	L04AB	ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS	IMMUNOSUPPRESSANTS	IMMUNOSUPPRESSANTS	Tumor necrosis factor alpha (TNF-a) inhibitors
